SAN
JOSE, Calif., Aug. 14,
2023 /PRNewswire/ -- Anixa Biosciences, Inc.
("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company
focused on the treatment and prevention of cancer, today announced
that Dr. Pamela D. Garzone, Anixa's
Chief Development Officer, has been invited to present at the
8th Annual CAR-TCR Summit being held from August 29 – September 1,
2023 in Boston, MA.
The 8th Annual CAR-TCR Summit is the world's pre-eminent
industry-leading comprehensive forum that unites the global cell
therapy community across a variety of cell types. During this
three-day event over one thousand attendees from over three hundred
companies will come together to explore discovery through
commercialization to deliver safe, effective and commercially
viable CAR and TCR therapies.
Entitled "Developing a CAR-T for Ovarian Cancer and Other Solid
Tumors," the presentation will focus on the opportunities and
challenges of CAR-T for solid tumors, routes of administration
besides intravenous infusions and details of the ovarian cancer
CAR-T therapy clinical trial (NCT05316129) under the direction of
Dr. Robert Wenham at Moffitt Cancer
Center and in collaboration with Anixa. This trial, a Phase I
clinical trial of autologous T cells genetically engineered
with a chimeric receptor to target the follicle-stimulating hormone
receptor (FSHR) in patients with recurrent ovarian cancer, will
evaluate intraperitoneal and intravenous administration of the
CAR-T and the role of lymphodepletion. The study commenced July of
2022 and is in progress.
Dr. Garzone will also be hosting a roundtable discussion titled,
"Impacting CAR-T Efficacy with Pre-Conditioning Regimens." Topics
covered during this roundtable will include discussion on
differences between lymphodepletion regimens and outcomes for
liquid and solid tumors, impact of lymphodeletion intensity on
CAR-T cell therapy, and how to achive optimal balance between
efficacy and safety.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists
of an ovarian cancer immunotherapy program that uses a novel type
of CAR-T known as chimeric endocrine receptor T cell (CER-T)
technology, and is being developed in collaboration with Moffitt
Cancer Center. The Company's vaccine portfolio includes a novel
vaccine being developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple negative breast cancer
(TNBC), the most lethal form of the disease – as well as a vaccine
to prevent ovarian cancer. These vaccine technologies focus on
immunizing against "retired" proteins that have been found to be
expressed in certain forms of cancer. Anixa's unique business
model of partnering with world-renowned research institutions on
clinical development allows the Company to continually examine
emerging technologies in complementary fields for further
development and commercialization. To learn more,
visit www.anixa.com or follow Anixa on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements
Statements that are not
historical fact may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are not statements of historical
facts, but rather reflect Anixa's current expectations
concerning future events and results. We generally use the words
"believes," "expects," "intends," "plans," "anticipates," "likely,"
"will" and similar expressions to identify forward-looking
statements. Such forward-looking statements, including those
concerning our expectations, involve risks, uncertainties and other
factors, some of which are beyond our control, which may cause our
actual results, performance or achievements, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contacts:
Stephen Kilmer
Investor Relations
skilmer@anixa.com
646-274-3580
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-invited-presentation-on-ovarian-cancer-car-t-therapy-at-the-8th-annual-car-tcr-summit-301899176.html
SOURCE Anixa Biosciences, Inc.